Characterization of a Brain Permeant Fluorescent Molecule and Visualization of Aβ Parenchymal Plaques, Using Real-Time Multiphoton Imaging in Transgenic Mice

[Image: see text] Emerging paradigms mandate discovery of imaging agents for diagnosing Alzheimer’s disease (AD) prior to appearance of clinical symptoms. To accomplish this objective, a novel heterocyclic molecule (4) was synthesized and validated as Aβ targeted probe. The agent shows labeling of n...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundaram, G.S.M., Garai, Kanchan, Rath, Nigam P., Yan, Ping, Cirrito, John R., Cairns, Nigel J., Lee, Jin-Moo, Sharma, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372081/
https://www.ncbi.nlm.nih.gov/pubmed/25003699
http://dx.doi.org/10.1021/ol501264q
Descripción
Sumario:[Image: see text] Emerging paradigms mandate discovery of imaging agents for diagnosing Alzheimer’s disease (AD) prior to appearance of clinical symptoms. To accomplish this objective, a novel heterocyclic molecule (4) was synthesized and validated as Aβ targeted probe. The agent shows labeling of numerous diffuse Aβ plaques in confirmed AD human brain tissues and traverses the blood–brain barrier to enable labeling of parenchymal Aβ plaques in live mice (APP(±)/PS1(±)) brains.

Ejemplares similares